Andrew Chan, MD, PhD

Accomplished immunologist and rheumatologist

Senior Vice President, Research–Biology, Genentech, Inc.

Sabin Auditorium and Zoom

---

About the Speaker

For more than three decades, Dr. Andrew Chan has helped shape the field of therapeutic antibody discovery and development. As senior vice president of Research–Biology at Genentech, Chan leads teams advancing groundbreaking research in oncology, immunology, ophthalmology, neuroscience and infectious diseases—work that continues to redefine how science transforms patient care. 

An accomplished immunologist and rheumatologist, Chan studies how the immune system defends against infection and how its dysregulation leads to autoimmune and inflammatory disorders. His pioneering research on B-cell biology contributed to the development of ocrelizumab (Ocrevus™), the first B-cell–directed therapy approved for both relapsing and progressive forms of multiple sclerosis. He has authored more than 100 scientific papers, reviews and books, and was named a Distinguished Fellow of the American Association of Immunologists in 2025. 

Beyond Genentech, Chan bridges academia, patient advocacy and industry. He serves as chair of the National Council at Washington University School of Medicine, chair of the Executive Advisory Board of the Chemistry Life Processes Institute at Northwestern University, and chair of the Scientific Advisory Board of the Lupus Research Alliance.